At the close on Monday, shares in Lexington, Massachusetts headquartered Agenus Inc. saw a drop of 2.93%, ending the day at $3.97, with a total trading volume of 1.15 million shares. The stock is trading below its 200-day moving average by 14.26%. Shares of the Company, which focuses on the discovery and development of treatments that engage the body's immune system for patients suffering with cancer, have a Relative Strength Index (RSI) of 17.53.
On October 27th, 2016, Agenus reported a net loss attributable to common stockholders of $40.8 million for Q3 2016, which includes $18.7 million of non-cash expenses. This compares to a net loss attributable to common stockholders for Q3 2015 of $13.2 million which included $4.1 million of non-cash income. Net loss was $0.47 per share for Q3 2016 compared to net loss of $0.16 per share for Q3 2015. Cash, cash equivalents, and short-term investments were $95.4 million as of September 30th, 2016.
On October 28th, 2016, research firm H.C. Wainwright downgraded the Company's stock rating from 'Buy' to 'Neutral'. The research firm also revised downwards its previous target price from $10 to $5. AGEN complete research report is just a click away and free at:
Shares in South San Francisco, California headquartered Portola Pharmaceuticals Inc. ended the day 9.24% lower at $18.18, with a total trading volume of 1.06 million shares. The stock is trading below its 50-day moving average by 15.01%. Shares of the Company, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have an RSI of 31.43.
On October 25th, 2016, Portola Pharmaceuticals announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market betrixaban for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. Betrixaban, an FDA Fast Track-designated investigational drug, is an oral, once-daily Factor Xa inhibitor anticoagulant. The complimentary report on PTLA can be downloaded at:
On Monday, shares in South San Francisco, California headquartered Tobira Therapeutics Inc. finished 0.65% higher at $42.09, with a total trading volume of 521,806 shares. The stock has advanced 5.91% in the last one month, 952.25% over the previous three months, and 318.81% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 66.20% and 236.26%, respectively. Additionally, shares of Tobira Therapeutics, which focuses on the development and commercialization of therapeutics to treat liver disease, inflammation, fibrosis, and HIV, have an RSI of 88.95.
On October 20th, 2016, Tobira Therapeutics announced the acceptance of the company's late breaking abstract as an oral presentation at the American Academy for the Study of Liver Diseases Annual Meeting (the Liver Meeting®), being held in Boston, MA from November 11th-15th, 2016. The abstract entitled "Cenicriviroc versus placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study," will be presented by Arun Sanyal, M.D., Charles Caravati Distinguished Professor and Chair, Division of Gastroenterology, Hepatology and Nutrition at Virginia Commonwealth University on November 14th, 2016. Sign up for your complimentary research report on TBRA at:
Zug, Switzerland-based Auris Medical Holding AG's shares recorded a trading volume of 245,480 shares at the end of yesterday's session and closed the day at $1.03, dropping 2.83%. The stock is trading below its 50-day moving average by 36.86%. Shares of the Company, which focuses on the development of novel products for the treatment of inner ear disorders, have an RSI of 23.29.
On October 11th, 2016, Auris Medical announced additional clinical data as well as updates to its development plan for KeyzilenTM (AM-101) in acute inner ear tinnitus. Based on insights from the recently completed TACTT2 trial, the Company is submitting a protocol amendment to regulatory agencies in Europe for TACTT3, the ongoing second Phase 3 clinical trial. In the amended trial protocol, the change in Tinnitus Functional Index (TFI) score will be elevated from a key secondary endpoint to an alternate primary efficacy endpoint. Top-line results from the expanded TACTT3 trial are now expected in early 2018. The outcomes from TACTT2 and the regulatory path forward will be reviewed with the US FDA in early December 2016. Get free access to your research report on EARS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
SOURCE Chelmsford Park SA